Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Olaf-Oliver Wolz"'
Autor:
Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D. Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O. Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 yea
Externí odkaz:
https://doaj.org/article/b801d4c67eeb429f80a7051c7f35eae6
Autor:
Olaf-Oliver Wolz, Dominik Vahrenhorst, Gianluca Quintini, Christina Lemberg, Sven D. Koch, Sarah-Katharina Kays, Lisa Walz, Neeraja Kulkarni, Michael Fehlings, Peter Wengenmayer, Jana Heß, Lidia Oostvogels, Sandra Lazzaro, Philipp von Eisenhart-Rothe, Philipp Mann
Publikováno v:
Vaccines, Vol 12, Iss 4, p 388 (2024)
Vaccines are highly effective at preventing severe coronavirus disease (COVID-19). With mRNA vaccines, further research is needed to understand the association between immunogenicity and reactogenicity, which is defined as the physical manifestation
Externí odkaz:
https://doaj.org/article/d3d07249b4984ba4b88e7f3d6c5f42c9
Autor:
Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels
Publikováno v:
Vaccine: X, Vol 14, Iss , Pp 100307- (2023)
Externí odkaz:
https://doaj.org/article/b348038516694a90b653418856f6e575
Autor:
Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels
Publikováno v:
Vaccine: X, Vol 11, Iss , Pp 100189- (2022)
Background: The COVID-19 vaccine candidate CVnCoV comprises sequence-optimized mRNA encoding SARS-CoV-2 S-protein encapsulated in lipid nanoparticles. In this phase 2a study, we assessed reactogenicity and immunogenicity of two or three doses in youn
Externí odkaz:
https://doaj.org/article/d56f1f88b42c415798b797e7768908f9
Autor:
Yamel Cardona Gloria, Stephan H. Bernhart, Sven Fillinger, Olaf-Oliver Wolz, Sabine Dickhöfer, Jakob Admard, Stephan Ossowski, Sven Nahnsen, Reiner Siebert, Alexander N. R. Weber
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Gain-of-function mutations of the TLR adaptor and oncoprotein MyD88 drive B cell lymphomagenesis via sustained NF-κB activation. In myeloid cells, both short and sustained TLR activation and NF-κB activation lead to the induction of inhibitory MYD8
Externí odkaz:
https://doaj.org/article/0caf074eea2a4d48b980452ed8e1c053
Autor:
Olaf-Oliver Wolz, Sarah-Katharina Kays, Helga Junker, Sven D. Koch, Philipp Mann, Gianluca Quintini, Philipp von Eisenhart-Rothe, Lidia Oostvogels
Publikováno v:
Vaccines, Vol 10, Iss 4, p 508 (2022)
A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18–60 and >60 years in a phase 2a clinical study. In the present s
Externí odkaz:
https://doaj.org/article/6d81e9606dfa4cba886cc929caf96069
Autor:
Annika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, Anton W. Langerak, Alice F. Muggen, Rainer Claus, Irina Bonzheim, Falko Fend, Helmut Rainer Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanović, Alexander N. R. Weber
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I pro
Externí odkaz:
https://doaj.org/article/6fbd23161b974b24849417e491c35159
Autor:
Olaf-Oliver Wolz, Sarah-Katharina Kays, Helga Junker, Sven D. Koch, Philipp Mann, Gianluca Quintini, Philipp von Eisenhart-Rothe, Lidia Oostvogels
A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18-60 and >60 years in a phase 2a clinical study. Here we report neu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5a5aef0c10fffe76148bd9151c4ae6f
https://doi.org/10.1101/2022.02.22.22271051
https://doi.org/10.1101/2022.02.22.22271051
Autor:
Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels
Publikováno v:
Vaccine: X. 11
The COVID-19 vaccine candidate CVnCoV comprises sequence-optimized mRNA encoding SARS-CoV-2 S-protein encapsulated in lipid nanoparticles. In this phase 2a study, we assessed reactogenicity and immunogenicity of two or three doses in younger and olde
Autor:
Dominik Vahrenhorst, Rolf Fendel, Mirjam Schunk, Jacobus J. Bosch, Julian J. Gabor, Mariola Fotin-Mleczek, Thirumalaisamy P. Velavan, Thomas Verstraeten, Geert Leroux-Roels, Christoph Schindler, Olaf-Oliver Wolz, Isabel Leroux-Roels, Peter G. Kremsner, Gianluca Quintini, P. Mann, Oliver Schoenborn-Kellenberger, Andrea Kreidenweiss, Arne Kroidl, Lidia Oostvogels, Lisa Walz, Stefan Mueller
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from convalescent sera and preclinical studies has identified the viral Spike (S) protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f63d2344a839873ae03c4568b63e50e7
https://doi.org/10.1101/2020.11.09.20228551
https://doi.org/10.1101/2020.11.09.20228551